%0 Journal Article
%T Mother to Child Transmission of HIV after Option B+ in Low Income Environment
%A Mve Koh Val¨¨re
%A Kamgaing Nelly
%A Nda Mefo
%A Foumane Pascal
%J Open Journal of Obstetrics and Gynecology
%P 1163-1175
%@ 2160-8806
%D 2018
%I Scientific Research Publishing
%R 10.4236/ojog.2018.812118
%X <strong>Background</strong><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><strong>:</strong></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> In Cameroon, the prevalence of HIV in pregnant
women was 7.8% in 2012, and they were 8500 HIV positive newborn</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">s</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> in
2013.</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">Option B+ is the first highly active antiretroviral therapy (HAART)
preventive protocol. The objective was to evaluate the rate of HIV transmission
on children born from mothers who were on Option B+ during pregnancy, in three
university teaching hospitals of the University of Yaound¨¦ I.</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><b><span style=\"font-family:Verdana;\">Methods</span></b></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><b><span style=\"font-family:Verdana;\">: </span></b></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">It was a retrospective, cross-sectional study over a
period of four years (2013-2017). We included HIV positive mothers not on
previous antiretroviral treatment and who received a single tablet daily of
combined tenofovir</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">(300</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">mg) + Lamivudine (300</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">mg) +</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span
%K Option B+
%K University of Yaound&#233
%K I
%K Cross Sectional
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=87854